Evidence map›Paper›PMID 37004643›Full record

ArticleInvestigational new drugs2023

Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer.

Rana Vafaei, Zohreh Khaki, Malihe Salehi, Neda Jalili, Mohammad Reza Esmailinejad, Ahad Muhammadnajad, Seyed Mahdi Nassiri, Alireza Vajhi, Shima Moradi Kalbolandi, Roya Mirzaei and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Rana VafaeiDepartment of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Zohreh KhakiDepartment of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran. zkhaki@ut.ac.ir.
Malihe SalehiRecombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Neda JaliliRecombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Mohammad Reza EsmailinejadDepartment of Surgery and Radiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Ahad MuhammadnajadCancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Mahdi NassiriDepartment of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Alireza VajhiDepartment of Surgery and Radiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Shima Moradi KalbolandiRecombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Roya MirzaeiRecombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Leila FarahmandRecombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. laylafarahmand@gmail.com.
Motamed Cancer Institute · IRUniversity of Tehran · IRAcademic Center for Education, Culture and Research · IRShahid Bahonar University of Kerman · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The usage of monoclonal antibodies (mAbs) and antibody fragments, as a matter associated with the biopharmaceutical industry, is increasingly growing. Harmonious with this concept, we designed an exclusive modeled single-chain variable fragment (scFv) against mesenchymal-epithelial transition (MET) oncoprotein. This scFv was newly developed from Onartuzumab sequence by gene cloning, and expression using bacterial host. Herein, we examined its preclinical efficacy for the reduction of tumor growth, invasiveness and angiogenesis in vitro and in vivo. Expressed anti-MET scFv demonstrated high binding capacity (48.8%) toward MET-overexpressing cancer cells. The IC

Indexed as

Breast NeoplasmsSingle-Chain AntibodiesAnimalsCell Line, TumorFemaleGenes, Tumor SuppressorHumansMiceSingle-Chain AntibodiesAntibody fragmentBreast CancerMETReceptor tyrosine kinaseRecombinantscFv

Identifiers

PMID37004643
OpenAlexW4362506087

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.